Immune cell therapy GT201 targets advanced tumors in early trial

NCT ID NCT06144671

Recruiting now Disease control Sponsor: Grit Biotechnology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental therapy called GT201, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced solid tumors. About 18 adults will receive the treatment to see if it is safe and can shrink tumors. The goal is to control the disease, not cure it, as ongoing management may still be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, China
The fifth medical center of the General Hospital of the Chinese people's Liberation Army
RECRUITING

Beijing, Beijing Municipality, China
Union Hospital Tongji Medical College Huazhong University Of Science And Technology
RECRUITING

Wuhan, Hubei, China
West China Hospital Sichuan University
RECRUITING

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.